These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

860 related articles for article (PubMed ID: 26753693)

  • 41. [Irritable bowel syndrome--irritable bowel or irritable mind?].
    Marlicz W; Zawada I; Starzyńska T
    Pol Merkur Lekarski; 2012 Jan; 32(187):64-9. PubMed ID: 22400184
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of harm in the pharmacotherapy of irritable bowel syndrome.
    Shah E; Kim S; Chong K; Lembo A; Pimentel M
    Am J Med; 2012 Apr; 125(4):381-93. PubMed ID: 22444104
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis.
    Menees SB; Maneerattannaporn M; Kim HM; Chey WD
    Am J Gastroenterol; 2012 Jan; 107(1):28-35; quiz 36. PubMed ID: 22045120
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea.
    Lembo A; Rao SSC; Heimanson Z; Pimentel M
    Clin Transl Gastroenterol; 2020 Mar; 11(3):e00144. PubMed ID: 32352714
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diarrhea-predominant irritable bowel syndrome: Diagnosis, etiology, and new treatment considerations.
    Lacy BE; Moreau JC
    J Am Assoc Nurse Pract; 2016 Jul; 28(7):393-404. PubMed ID: 27436200
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections.
    Gerard L; Garey KW; DuPont HL
    Expert Rev Anti Infect Ther; 2005 Apr; 3(2):201-11. PubMed ID: 15918778
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Board Review Vignette: Irritable Bowel Syndrome.
    Talley NJ
    Am J Gastroenterol; 2016 Sep; 111(9):1223-5. PubMed ID: 27527743
    [No Abstract]   [Full Text] [Related]  

  • 48. Biologic properties and clinical uses of rifaximin.
    DuPont HL
    Expert Opin Pharmacother; 2011 Feb; 12(2):293-302. PubMed ID: 21226639
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial.
    Pimentel M; Park S; Mirocha J; Kane SV; Kong Y
    Ann Intern Med; 2006 Oct; 145(8):557-63. PubMed ID: 17043337
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS.
    Lacy BE
    Neurogastroenterol Motil; 2016 Jan; 28(1):26-35. PubMed ID: 26690872
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The safety of novel drugs used to treat irritable bowel syndrome.
    Mozaffari S; Nikfar S; Abdollahi M
    Expert Opin Drug Saf; 2014 May; 13(5):625-38. PubMed ID: 24669839
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diarrhea-Predominant and Constipation-Predominant Irritable Bowel Syndrome: Current Prescription Drug Treatment Options.
    Wechsler EV; Shah ED
    Drugs; 2021 Nov; 81(17):1953-1968. PubMed ID: 34727333
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antibiotic treatment of constipation-predominant irritable bowel syndrome.
    Pimentel M; Chang C; Chua KS; Mirocha J; DiBaise J; Rao S; Amichai M
    Dig Dis Sci; 2014 Jun; 59(6):1278-85. PubMed ID: 24788320
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea.
    DuPont HL; Jiang ZD; Okhuysen PC; Ericsson CD; de la Cabada FJ; Ke S; DuPont MW; Martinez-Sandoval F
    Ann Intern Med; 2005 May; 142(10):805-12. PubMed ID: 15897530
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women.
    Fukudo S; Kinoshita Y; Okumura T; Ida M; Akiho H; Nakashima Y; Nishida A; Haruma K
    Gastroenterology; 2016 Feb; 150(2):358-66.e8. PubMed ID: 26551550
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome.
    Chang FY; Lu CL; Chen CY; Luo JC
    J Gastroenterol Hepatol; 2007 Dec; 22(12):2266-72. PubMed ID: 17559369
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rifaximin: a new treatment for travelers' diarrhea.
    Pakyz AL
    Ann Pharmacother; 2005 Feb; 39(2):284-9. PubMed ID: 15598963
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel pharmacological therapies for irritable bowel syndrome.
    Corsetti M; Whorwell P
    Expert Rev Gastroenterol Hepatol; 2016 Jul; 10(7):807-15. PubMed ID: 26907518
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity.
    Pimentel M; Cash BD; Lembo A; Wolf RA; Israel RJ; Schoenfeld P
    Dig Dis Sci; 2017 Sep; 62(9):2455-2463. PubMed ID: 28589238
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rifaximin in the treatment of irritable bowel syndrome: is there a high risk for development of antimicrobial resistance?
    Farrell DJ
    J Clin Gastroenterol; 2013 Mar; 47(3):205-11. PubMed ID: 23340064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.